ASPEN: Long-Term Follow-up Results of a Phase 3 Randomized Trial of Zanubrutinib (ZANU) vs Ibrutinib (IBR) in Patients (PTS) with Waldenström Macroglobulinemia (WM)

Quizartinib Prolonged Survival vs Placebo Plus Intensive Induction and Consolidation Therapy Followed by Single-Agent Continuation in Patients Aged 18-75 Years with Newly Diagnosed FLT3-ITD+ AML

SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib (ZANU) versus Bendamustine + Rituximab (BR) in Patients (PTS) with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study

Subcutaneous Epcoritamab with Rituximab + Lenalidomide (R2) in Patients (PTS) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Update from Phase 1/2 Trial

Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (POLA-R-CHP) versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL): Results from the Phase III Polarix Study

Epcoritamab (EPCO) with Gemcitabine + Oxaliplatin (GEMOX) in Patients (PTS) with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Ineligible for Autologous Stem Cell Transplant (ASCT) Induces High Response Rate Even in Pts Failing CAR T Therapy

First-Line Brentuximab Vedotin Plus Chemotherapy Improves Overall Survival in Patients with Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1

First-line Treatment (TX) with Subcutaneous (SC) Epcoritamab (EPCO) + R-CHOP in Patients (PTS) with High-Risk Diffuse Large B-cell Lymphoma (DLBCL): Phase 1/2 Data Update

Subcutaneous epcoritamab + R-DHAX/C in Patients (PTS) with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplant (ASCT): Preliminary Phase 1/2 Results

Venetoclax-Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia: 5-year Results of the Randomized CLL 14 Study

CB-010, a CRISPR-edited Allogeneic Anti-CD19 Car -T Cell Therapy with a PD-1 Knock Out, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Study)

Pharmacokinetics and Pharmacodynamics in First-MIND: A Phase IB, Openlabel, Randomized Study of Tafasitamab ± Lenalidomide+ R‑CHOP in Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma

Pirtobrutinib, a Highly Selective, Non-Covalent (REVERSIBLE) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study

Zanubrutinib in 13 Acalabrutinib-Intolerant Patients (PTS) with B-cell Malignancies